Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to this medicine from other glucose-lowering agents. Since this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients, Patient subsection).
Improves glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes with difficult blood sugar control
cardiovascular diseases
cardiovascular risk factors
View approved original textHide original text
This medication contains dapagliflozin and metformin, which effectively help control blood sugar levels in adult patients with type 2 diabetes. When used in conjunction with diet and exercise, it greatly aids in blood sugar management. It can be used in patients who have cardiovascular diseases or risk factors, particularly those with poorly controlled blood sugar. However, it is advisable to refer to information intended for professionals regarding matters related to cardiovascular events. This medication improves blood sugar control in patients with type 2 diabetes.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to this medicine from other glucose-lowering agents. Since this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients, Patient subsection).
Precautions
This medication helps control blood sugar levels. However, it can rarely cause a condition called lactic acidosis, and should not be administered to patients with impaired kidney function or specific health conditions. Additionally, caution should be exercised when used with insulin or other diabetes treatments, as hypoglycemic symptoms may occur. Patients with decreased kidney function or low fluid volume should periodically check kidney function and blood pressure while using this medication. This medication may increase the risk of genital infections and urinary tract infections, so if any infection symptoms occur, immediate consultation with healthcare professionals is necessary. The metformin component should not be used in patients with impaired liver function or those experiencing dehydration or severe infections. Women who are pregnant or breastfeeding should not take this medication, and it should be discontinued if pregnancy is planned or confirmed. It is advisable to avoid alcohol consumption while taking this medication, and to refrain from skipping meals or overexercising to prevent hypoglycemic symptoms. When administering this medication to elderly patients, dosage adjustment and careful monitoring should be considered due to the possibility of reduced kidney function. In case of overdose, immediate medical attention should be sought, and dialysis treatment may be beneficial if necessary. Lastly, caution should be taken as symptoms like dizziness may occur while driving or operating machinery during the course of this medication.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 84 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
low back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
increased hematocrit
reduced renal creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
lung malignant neoplasm
uterine fibroid
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
sensory disturbances
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
elevated blood sugar
tendinitis
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periarticular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
swelling
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
itching
palpitations
insomnia
type 2a hyperlipoproteinemia
neurogenic hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is advisable to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.